0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Brief Communications |

Inhaled or Reduced-Dose Intravenous Pentamidine for Pneumocystis carinii Pneumonia: A Pilot Study

JOHN E. CONTE Jr., M.D.; HARRY HOLLANDER, M.D.; and JEFFREY A. GOLDEN, M.D.
[+] Article and Author Information

Grant support: in part by grant RR-79 from the Division of Research Resources, Public Health Service, and by LyphoMed, Inc.

▸Requests for reprints should be addressed to John E. Conte, Jr., M.D.; Box 0208; or Jeffrey A. Golden, M.D., Box 0326; Department of Medicine, University of California at San Francisco; San Francisco, CA 94143.


San Francisco, California


Ann Intern Med. 1987;107(4):495-498. doi:10.7326/0003-4819-107-4-495
Text Size: A A A

Study Objective: To evaluate inhaled or reduced-dose intravenous pentamidine for the treatment of patients with mild Pneumocystis carinii pneumonia.

Design: Open, nonrandomized pilot study; measurement of pentamidine concentrations in plasma and bronchoalveolar lavage fluid.

Patients: Of 22 men with mild P. carinii pneumonia (Po2 ≥ 55 mm Hg), 15 (9 in the inhaled group and 6 in the intravenous group) received treatment for their first episode and 7 for a repeat episode.

Interventions: Pentamidine isethionate, 4 mg/kg body weight by inhalation, or 3 mg/kg intravenously, was given once daily, as long as clinically indicated.

Measurements and Main Results: Of the 13 patients in the inhaled group, 9 had a satisfactory response; and of the 10 in the reduced-dose intravenous group, 9 had a satisfactory response. Major adverse reactions occurred in two patients in each group. Three patients in the inhaled group appeared to have had early relapses. Bronchoalveolar lavage fluid concentrations of pentamidine ranged between 16.8 ± 7.3 ng/mL and 149.7 ± 38.2 ng/mL in the inhaled group and 3.4 ± 0.2 ng/mL and 10.9 ng/mL in the intravenous group.

Conclusions: Inhaled or reduced-dose intravenous pentamidine may be an effective and less toxic therapy for mild P. carinii pneumonia. These regimens are not recommended for general use until larger controlled trials are conducted.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)